Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Outstanding (2022 - 2025)

NewAmsterdam Pharma's Shares Outstanding history spans 4 years, with the latest figure at $114.4 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 5.86% year-over-year to $114.4 million; the TTM value through Dec 2025 reached $114.4 million, up 5.86%, while the annual FY2025 figure was $114.4 million, 5.86% up from the prior year.
  • Shares Outstanding for Q4 2025 was $114.4 million at NewAmsterdam Pharma, up from $113.2 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $114.4 million in Q4 2025 and bottomed at $81.8 million in Q1 2023.
  • The 4-year median for Shares Outstanding is $90.0 million (2024), against an average of $95.7 million.
  • The largest annual shift saw Shares Outstanding fell 0.89% in 2023 before it soared 31.04% in 2024.
  • A 4-year view of Shares Outstanding shows it stood at $83.2 million in 2022, then fell by 0.89% to $82.5 million in 2023, then surged by 31.04% to $108.1 million in 2024, then grew by 5.86% to $114.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Shares Outstanding are $114.4 million (Q4 2025), $113.2 million (Q3 2025), and $112.5 million (Q2 2025).